These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 25742078)
1. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination. Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078 [TBL] [Abstract][Full Text] [Related]
2. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323 [TBL] [Abstract][Full Text] [Related]
3. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167 [TBL] [Abstract][Full Text] [Related]
4. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575 [TBL] [Abstract][Full Text] [Related]
5. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Stoof SP; Heijstek MW; Sijssens KM; van der Klis F; Sanders EA; Teunis PF; Wulffraat NM; Berbers GA Ann Rheum Dis; 2014 Apr; 73(4):728-34. PubMed ID: 23505231 [TBL] [Abstract][Full Text] [Related]
6. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612 [TBL] [Abstract][Full Text] [Related]
7. Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children. Badahdah AM; Khatami A; Tashani M; Rashid H; Booy R Pediatr Infect Dis J; 2018 Mar; 37(3):e66-e71. PubMed ID: 29227467 [TBL] [Abstract][Full Text] [Related]
8. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool. Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925 [TBL] [Abstract][Full Text] [Related]
9. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine. van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552 [TBL] [Abstract][Full Text] [Related]
10. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM BMC Med Res Methodol; 2019 Jan; 19(1):1. PubMed ID: 30611213 [TBL] [Abstract][Full Text] [Related]
11. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725 [TBL] [Abstract][Full Text] [Related]
12. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288 [TBL] [Abstract][Full Text] [Related]
13. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination. van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957 [TBL] [Abstract][Full Text] [Related]
14. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali. Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687 [TBL] [Abstract][Full Text] [Related]
15. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554 [TBL] [Abstract][Full Text] [Related]
16. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645 [TBL] [Abstract][Full Text] [Related]
17. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents. Quiambao BP; Bavdekar A; Dubey AP; Jain H; Kolhe D; Bianco V; Miller JM; Van der Wielen M Hum Vaccin Immunother; 2017 Mar; 13(3):636-644. PubMed ID: 28152332 [TBL] [Abstract][Full Text] [Related]
18. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. de Voer RM; Mollema L; Schepp RM; de Greeff SC; van Gageldonk PG; de Melker HE; Sanders EA; Berbers GA; van der Klis FR PLoS One; 2010 Aug; 5(8):e12144. PubMed ID: 20730091 [TBL] [Abstract][Full Text] [Related]
19. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years. Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM Hum Vaccin Immunother; 2012 Dec; 8(12):1882-91. PubMed ID: 23032168 [TBL] [Abstract][Full Text] [Related]
20. Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil. Andrade AL; Minamisava R; Tomich LM; Lemos AP; Gorla MC; de Cunto Brandileone MC; Domingues CMS; de Moraes C; Policena G; Bierrenbach AL; Vaccine; 2017 Apr; 35(16):2025-2033. PubMed ID: 28318769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]